UAE Becomes First Country to Approve Oral Treatment for Non-Segmental Vitiligo.”

The United Arab Emirates has become the first country in the world to approve an oral treatment specifically for non-segmental vitiligo, giving eligible patients a new option for managing a condition that causes patches of skin to lose their pigment.

The Emirates Drug Establishment (EDE) approved an expanded indication for RINVOQ (upadacitinib) for adults and adolescents aged 12 and above with non-segmental vitiligo who are candidates for systemic treatment. The medicine is taken once daily, according to UAE health authorities.

The decision marks an important development in the treatment of vitiligo, particularly for patients with more extensive disease who may require medication that works throughout the body rather than treatments applied only to affected areas. The EDE said the UAE's early approval reflects its effort to make newer pharmaceutical treatments available to patients quickly.

Vitiligo occurs when melanocytes, the cells responsible for producing skin pigment, are lost or destroyed. The resulting white patches can appear on different parts of the body and may spread over time. Non-segmental vitiligo is the most common form and can affect the face, hands, arms, legs and other areas. The condition is not contagious, but its visible nature can have significant psychological and social consequences.

RINVOQ is not a new medicine. Upadacitinib, a Janus kinase (JAK) inhibitor developed by AbbVie, has already been authorised in several markets for a range of inflammatory and autoimmune conditions. What is new is its approved use for non-segmental vitiligo. The European Medicines Agency's medicines committee also issued a positive opinion in June recommending this indication for adults and adolescents aged 12 and older who are candidates for systemic therapy.

That distinction is important because the UAE's claim to being first relates to regulatory approval of the expanded use, rather than the discovery of an entirely new drug. The European process, for example, had already produced a positive recommendation by June, although the UAE's announcement on August 17 came before the European Commission's final decision on the corresponding marketing-authorisation change.

For patients, the development could be particularly relevant where topical treatment is insufficient or impractical. Dermatology specialist Dr Rekha Santosh, speaking to The National, described the approval as an important development because treatment options for people with more extensive vitiligo have remained limited.

There is, however, an important medical qualification. An approval does not mean that RINVOQ is a cure for vitiligo or that it is suitable for everyone with the condition. Upadacitinib is a systemic immunomodulating medicine and its use is subject to medical assessment and prescribing criteria. Regulators in other markets have also maintained safety warnings and monitoring requirements around JAK inhibitors, underscoring the need for doctors to weigh potential benefits against risks for individual patients.

The UAE's decision also arrives as research into oral treatments for vitiligo is accelerating. Other JAK inhibitors are being studied for the condition, while clinical research continues to examine how systemic medicines might be combined with therapies such as narrowband ultraviolet-B phototherapy to improve repigmentation. Recent research reviews say oral JAK inhibitors show promise, but also point to the need for longer-term evidence on safety, treatment protocols and durability of results.

For millions of people living with vitiligo, the significance of the UAE approval therefore goes beyond the introduction of one additional medicine. It signals a shift toward more targeted systemic approaches to a condition that has historically had limited treatment choices, while also highlighting the continuing need for careful long-term research. As more regulators consider similar applications, the UAE's decision could become an early marker in a broader transformation of how non-segmental vitiligo is treated worldwide.